Mark Slifstein
Overview
Explore the profile of Mark Slifstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
124
Citations
6132
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ananth M, Gardus J, Huang C, Palekar N, Slifstein M, Zaborszky L, et al.
Cell Rep
. 2025 Feb;
44(2):115249.
PMID: 39891909
Structural and functional changes in the entorhinal cortex (EC) are among the earliest signs of cognitive aging. Here, we ask whether a compromised cholinergic system influences early EC impairments and...
2.
Williams J, Tubiolo P, Gil R, Zheng Z, Silver-Frankel E, Haubold N, et al.
medRxiv
. 2025 Jan;
PMID: 39763546
Background: Converging evidence from clinical neuroimaging and animal models has strongly implicated dysfunction of thalamocortical circuits in the pathophysiology of schizophrenia. Preclinical models of genetic risk for schizophrenia have shown...
3.
Slifstein M, Qu W, Gil R, Weinstein J, Perlman G, Jaworski-Calara T, et al.
Neuropsychopharmacology
. 2024 Aug;
49(13):2087-2093.
PMID: 39217267
The kappa opioid receptor (KOR) and its endogenous agonist dynorphin have been implicated in multiple psychiatric conditions including psychotic disorders. We tested the hypotheses that kappa expression is elevated and...
4.
Weinstein J, Moeller S, Perlman G, Gil R, Van Snellenberg J, Wengler K, et al.
Biol Psychiatry
. 2024 Feb;
96(5):352-364.
PMID: 38309322
Background: Despite longstanding interest in the central cholinergic system in schizophrenia (SCZ), cholinergic imaging studies with patients have been limited to receptors. Here, we conducted a proof-of-concept positron emission tomography...
5.
Ananth M, Gardus J, Huang C, Palekar N, Slifstein M, Zaborszky L, et al.
Res Sq
. 2024 Jan;
PMID: 38260541
In a series of translational experiments using fully quantitative positron emission tomography (PET) imaging with a new tracer specific for the vesicular acetylcholine transporter ([F]VAT) in vivo in humans, and...
6.
Medial Prefrontal Cortex Dysfunction Mediates Working Memory Deficits in Patients With Schizophrenia
Williams J, Zheng Z, Tubiolo P, Luceno J, Gil R, Girgis R, et al.
Biol Psychiatry Glob Open Sci
. 2023 Oct;
3(4):990-1002.
PMID: 37881571
Background: Schizophrenia (SCZ) is marked by working memory (WM) deficits, which predict poor functional outcome. While most functional magnetic resonance imaging studies of WM in SCZ have focused on the...
7.
Hu B, Akula H, Noh D, Mui Y, Slifstein M, Parsey R, et al.
J Labelled Comp Radiopharm
. 2023 Aug;
66(12):384-392.
PMID: 37615234
The vesicular acetylcholine transporter (VAChT) in the brain is an important presynaptic cholinergic biomarker, and neuroimaging studies of VAChT may provide in vivo information about psychiatric and neurologic conditions including...
8.
Slifstein M, Abi-Dargham A
Biol Psychiatry
. 2023 May;
93(12):1056-1058.
PMID: 37257982
No abstract available.
9.
Rutherford B, Choi J, Slifstein M, OBoyle K, Abi-Dargham A, Brown P, et al.
J Affect Disord
. 2023 Mar;
330:369.
PMID: 36966032
No abstract available.
10.
Rosell D, Slifstein M, Thompson J, Xu X, Perez-Rodriguez M, McClure M, et al.
Psychopharmacology (Berl)
. 2023 Jan;
240(2):361-371.
PMID: 36640190
Rationale: Characterizing the neuroanatomical basis of serotonergic abnormalities in severe, chronic, impulsive aggression will allow for rational treatment selection, development of novel therapeutics, and biomarkers to identify at-risk individuals. Objectives:...